A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of R-TPR-015 (1422015) in Patients With Active Rheumatoid Arthritis on stable dose of Methotrexate.

Trial Profile

A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of R-TPR-015 (1422015) in Patients With Active Rheumatoid Arthritis on stable dose of Methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors EPIRUS Biopharmaceuticals; Reliance Life Sciences
  • Most Recent Events

    • 13 Jun 2015 Results (Secondary Efficacy Outcomes )presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2015 Pooled safety data from this trial and a phase 1 trial in male volunteers presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top